drugset / Trial / NCT00513968
Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and immunogenicity of a novel mixed plasmid DNA (HB-110) combined with an antiviral agent (Adefovir) for the patients with chronic Hepatitis B infection.
Timeline
- Start
- 2007-07
- Primary completion
- 2010-04
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adefovir | Unknown | 10 mg | Oral |
| Subject | HB-110 | Vaccine | 2 mg | Intramuscular |
| Subject | HB-110 | Vaccine | 4 mg | Intramuscular |
| Subject | HB-110 | Vaccine | 8 mg | Intramuscular |